GENENTECH, INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of RG7667 in Healthy Volunteers
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT01496755
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 501
- Registration Number
- NCT01493843
- Locations
- πΊπΈ
Franklin Square Hospital, Baltimore, Maryland, United States
π¦πΊRoyal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia
ππΊOrszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01487239
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT01485861
- Locations
- πΊπΈ
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
πΊπΈKaiser Permanente Medical Ctr, Honolulu, Hawaii, United States
π¨πΏVseobecna fakultni nemocnice v Praze, Praha 2, Czechia
Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01480310
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01474668
Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01473316
A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01469793
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT01461317
- Locations
- πΊπΈ
University of California, San Diego, La Jolla, California, United States
πΊπΈAtlanta Gastroenterology Associates, Atlanta, Georgia, United States
πΊπΈLong Island Clin Rsch Asc, LLP, Great Neck, New York, United States
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01455493
Β© Copyright 2024. All Rights Reserved by MedPath